New York Oncology Hematology

What New York Oncology Hematology does

New York Oncology Hematology (NYOH) is a physician-owned private oncology and hematology practice headquartered in Albany, New York, and operating as the largest cancer and blood disorder treatment center in the United States. Founded in 1985, the practice serves patients across New York's Capital Region, Southern Vermont, and Western Massachusetts through seven clinical locations, with services spanning medical oncology, hematology, radiation oncology, gynecologic oncology, neuro-oncology, and diagnostic imaging. NYOH operates an integrated care model anchored by PET-CT imaging, linear accelerators for radiation therapy, an in-office laboratory, and an NCODA-accredited Medically Integrated Dispensary for oral oncology medications, with 25 active clinical trials and a research track record of participation in over 500 trials contributing to 50 FDA-approved cancer treatments over four decades.

NYOH's revenue model is anchored in fee-for-service medical oncology and hematology care billed to insurance, supplemented by clinical trial agreements with pharmaceutical sponsors (notably through its affiliation with The US Oncology Network), diagnostic imaging, and ancillary services such as telemedicine and in-office medication dispensing. Its go-to-market combines a sales-led physician referral network with direct-to-consumer channels including website appointment requests, a patient portal, telemedicine virtual visits, and community-based outreach such as support groups and survivorship programming. The practice is differentiated by sub-specialized physicians, multidisciplinary treatment under one roof, and a growing portfolio of advanced modalities that now includes commercial CAR-T cell therapy (administered locally for the first time in April 2025).

The practice is undergoing a major capacity expansion through the construction of a $52 million, 105,000 square-foot, three-story Regional Cancer Center in Guilderland, NY, which broke ground in June 2025 and is scheduled to open in early 2027. The new facility is sized for 50+ providers, 150+ support staff, 80 infusion pods, two linear accelerators, and CT and PET scanners, and is intended to become the largest and most comprehensive cancer treatment facility in the Capital Region. NYOH has pursued parallel capability and partnership expansions, including the MYLUNG Consortium for precision NSCLC research, a research collaboration with AstraZeneca, NIH, and St. Peter's Hospital, and a relationship with MD Anderson Cancer Center to maintain clinical trial continuity for patients.

Name

New York Oncology Hematology

Legal name

New York Oncology Hematology

Website

https://newyorkoncology.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

251–500 employees

Short description

New York Oncology Hematology is a physician-owned private oncology and hematology practice and the largest cancer treatment center in the United States, serving patients across New York's Capital Region, Southern Vermont, and Western Massachusetts with integrated medical, radiation, and surgical oncology services.

Ownership category

akta.pro rank

Product category

Oncology and Hematology Services

NAICS

Offices of Physicians (62111), Medical and Diagnostic Laboratories (62151), Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), Services-Medical Laboratories (8071)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Hematologic Oncology (Leukemia/Lymphoma/Myeloma) (HLAKAFAD), Neuro-oncology (HLAKAIAL)

Keywords

• Oncology hematology services
• Cancer treatment center
• Radiation oncology
• Clinical research trials
• Blood disorder care

Headquarters

HQ city

Albany

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Medical Services: Professional and facility fees for oncology and hematology services including chemotherapy, radiation therapy, consultations, and diagnostic procedures billed to insurance
2. Clinical Trial Services: Research-related services potentially compensated through clinical trial agreements with pharmaceutical partners
3. Diagnostic Imaging Services: PET/CT imaging and other diagnostic services billed to insurance

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

New York Oncology Hematology (NYOH) is a physician-owned private oncology and hematology practice that diagnoses and treats cancer and blood disorders through medical oncology, radiation oncology, hematology, gynecologic oncology, and neuro-oncology services. The practice delivers chemotherapy, immunotherapy, targeted therapy, CAR-T cell therapy, stem cell transplantation, and radiation therapy across seven regional clinics, supported by diagnostic imaging, an in-office laboratory, an NCODA-accredited Medically Integrated Dispensary, and an active clinical trials program.

Product overview

New York Oncology Hematology (NYOH) is a comprehensive oncology and hematology practice offering a unified portfolio of cancer care services across multiple locations in New York's Capital Region. The core offering includes medical oncology, hematology, radiation oncology, gynecologic oncology, and neuro-oncology services, supported by advanced treatment modalities such as chemotherapy, immunotherapy, targeted therapy, CAR-T cell therapy, and stem cell transplantation. The practice operates an integrated care model combining clinical research trials, diagnostic imaging, telemedicine, in-office laboratory services, and an NCODA-accredited Medically Integrated Dispensary. NYOH is constructing a new 105,000 square foot Regional Cancer Center (opening 2027) that will serve as the flagship facility, while maintaining existing locations in Clifton Park, Albany, Amsterdam, Troy, and Hudson.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Oncology Comprehensive medical oncology services providing chemotherapy, immunotherapy, hormone therapy, and targeted therapy treatments for various cancer types, serving adult oncology patients.
• Hematology Specialized care for blood disorders including leukemia, lymphoma, multiple myeloma, and benign hematologic conditions, serving adult hematology patients.
• Radiation Oncology Advanced radiation therapy treatments including IMRT, IGRT, stereotactic radiosurgery, and prostate seed implants, delivered using linear accelerators.
• Gynecologic Oncology and Surgery Specialized treatment for gynecologic cancers including ovarian, cervical, endometrial, and vulvar cancers, including surgical interventions, serving women with gynecologic malignancies.
• Neuro-oncology Specialized care for brain and spine cancers, including treatment of malignant gliomas, for patients with central nervous system malignancies.
• Chemotherapy and Infusion Therapy Traditional chemotherapy and infusion therapy treatments administered in outpatient settings for cancer patients.
• Immunotherapy Cancer treatment that uses the patient's immune system to fight cancer cells, offered as part of NYOH's treatment portfolio.
• Targeted Therapy Precision cancer treatment that targets specific genes, proteins, or the tissue environment contributing to cancer growth.
• CAR T-Cell Therapy Advanced cellular therapy where a patient's cells are removed, genetically modified in a lab, and returned to fight cancer; NYOH administered the first commercial CAR-T treatment in the Capital Region in April 2025.
• Bone Marrow and Stem Cell Transplant Outpatient stem cell transplant program for blood cancers and disorders, the only such program available in the Capital Region at NYOH.
• Clinical Research and Trials Program Comprehensive clinical research program offering 25 active trials across 10 cancer types; NYOH has participated in over 500 trials contributing to 50 FDA-approved cancer therapies over 30 years.
• Diagnostic Imaging Advanced imaging services including PET-CT scans and CT imaging for cancer detection, staging, and monitoring.
• Telemedicine Virtual consultation services allowing new and existing patients to consult with NYOH physicians via secure virtual visits.
• In-Office Laboratory Services On-site laboratory testing providing convenient specimen collection and results for patients during treatment.
• Medically Integrated Dispensary NCODA Center of Excellence accredited oral medication dispensing pharmacy providing convenient prescription dispensing including drive-through service to patients at clinic locations.
• Hereditary Cancer Risk Assessment Program Genetic testing and assessment program providing insight into possible genetic causes of cancer types for at-risk patients and families.
• Palliative Care Specialty care focused on relieving symptoms and reducing stress associated with cancer treatment, improving patient quality of life.
• Survivorship Program Long-term follow-up care and survivorship planning for cancer patients after completion of treatment.

Named customers4 records

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core.

• MYLUNG ConsortiumcoreStrategic or Co-development Partner · 11 February 2021Community-based research consortium to advance precision medicine options for non-small cell lung cancer (NSCLC) patients.
• St. Peter's HospitalcoreStrategic or Co-development Partner · 5 June 2020Partnership to test acalabrutinib cancer drug on COVID-19 patients. Three patients were treated at St. Peter's Hospital under this collaboration, with results published in Science Immunology journal.
• AstraZenecacoreStrategic or Co-development Partner · 5 June 2020Collaboration on acalabrutinib COVID-19 research. AstraZeneca partnered with US Oncology Research to develop targeted therapies including acalabrutinib.
• National Institutes of HealthcoreStrategic or Co-development Partner · 5 June 2020NIH collaborated on the acalabrutinib COVID-19 research study published in Science Immunology.
• MD Anderson Cancer CentercoreStrategic or Co-development Partner · 1 May 2020Partnership to keep patient on clinical trial during COVID-19 pandemic. NYOH worked with MD Anderson in Texas to maintain patient's treatment continuity.
• The US Oncology NetworkcoreStrategic or Co-development PartnerNYOH is affiliated with The US Oncology Network, participating in collaborative clinical research and accessing resources of the network.

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Texas Oncology: Largest US Oncology Network–affiliated community oncology practice, operating across 200+ Texas sites with medical oncology, radiation oncology, gynecologic oncology, and clinical research. Closely comparable to NYOH on sub-specialization, USON affiliation, and advanced-therapy delivery, with similar service mix and infrastructure footprint.
• Florida Cancer Specialists & Research Institute: Large, physician-owned, multi-site community oncology and hematology practice with deep clinical trial operations across Florida. Mirrors NYOH's combination of sub-specialized oncology, USON research participation, dispensing, and independent physician ownership.
• Regional Cancer Care Associates: Multi-site community oncology practice across the Northeast with medical oncology, radiation oncology, and clinical trials. Geographic and operational overlap with NYOH as a regional community oncology group delivering similar service mix in adjacent markets.
• New York Cancer & Blood Specialists: Long Island–based community oncology practice offering medical oncology, hematology, radiation, and clinical research across multiple New York sites. Direct competitor in New York state with comparable private-practice model, service breadth, and physician sub-specialization.
• Compass Oncology: US Oncology Network–affiliated multi-specialty community oncology practice in Oregon and Washington. Comparable to NYOH in scale, USON affiliation, integrated clinical research program, and comprehensive sub-specialized cancer care delivery.
• Arizona Oncology: US Oncology Network–affiliated community oncology practice operating across multiple Arizona sites with medical oncology, radiation, gyn-onc, and clinical trials. Closely analogous to NYOH on USON affiliation, sub-specialization, and multi-site physician-owned structure.

Broad incumbents

• OneOncology: PE-backed national platform partnering with independent community oncology practices; provides practice management, payer contracting, and clinical trial infrastructure. Directly comparable operating model to NYOH's aspiration of scale plus independence, though platform-level rather than single-practice.
• Roswell Park Comprehensive Cancer Center: National Cancer Institute–designated comprehensive cancer center in Buffalo, NY. Comparable to NYOH on oncology research output and advanced therapies, though operating as an academic/research institution rather than a community practice.
• Memorial Sloan Kettering Cancer Center: NCI-designated comprehensive cancer center based in New York City offering medical oncology, radiation, surgical oncology, and a deep clinical research program. Relevant as the academic referral destination competing for advanced-therapy cases that NYOH is increasingly retaining in-region.

Regional players

• Willamette Valley Cancer Institute: US Oncology Network–affiliated community oncology practice in Oregon offering medical oncology, hematology, radiation, and clinical research. Comparable model and service breadth; relevant as a regional analog to NYOH rather than a direct geographic competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about New York Oncology Hematology